BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15714492)

  • 1. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
    Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
    Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.
    Zeuzem S; Lee JH; Roth WK
    Hepatology; 1997 Mar; 25(3):740-4. PubMed ID: 9049228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2009 Jun; 81(6):1032-9. PubMed ID: 19382270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.
    Kurosaki M; Enomoto N; Murakami T; Sakuma I; Asahina Y; Yamamoto C; Ikeda T; Tozuka S; Izumi N; Marumo F; Sato C
    Hepatology; 1997 Mar; 25(3):750-3. PubMed ID: 9049230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma.
    Takeyasu M; Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2012 Aug; 84(8):1199-207. PubMed ID: 22711347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C.
    Fukutomi T; Fukutomi M; Iwao M; Watanabe H; Tanabe Y; Hiroshige K; Kinukawa N; Nakamuta M; Nawata H
    Med Sci Monit; 2000; 6(4):692-8. PubMed ID: 11208393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.
    Patton HM; Patel K; Behling C; Bylund D; Blatt LM; Vallée M; Heaton S; Conrad A; Pockros PJ; McHutchison JG
    J Hepatol; 2004 Mar; 40(3):484-90. PubMed ID: 15123364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C.
    Tachi Y; Katano Y; Honda T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Samejima Y; Goto H
    Liver Int; 2010 Apr; 30(4):554-9. PubMed ID: 19951380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
    Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
    Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
    Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
    Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C.
    Karino Y; Toyota J; Sugawara M; Higashino K; Sato T; Ohmura T; Suga T; Okuuchi Y; Matsushima T
    Am J Gastroenterol; 1997 Jan; 92(1):61-5. PubMed ID: 8995939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C.
    Liu CJ; Jeng YM; Chen PJ; Lai MY; Yang HC; Huang WL; Kao JH; Chen DS
    Antivir Ther; 2005; 10(3):405-15. PubMed ID: 15918331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.
    Antúnez I; Aponte N; Fernández-Carbia A; Rodríguez-Perez F; Toro DH
    P R Health Sci J; 2004 Jun; 23(2 Suppl):57-60. PubMed ID: 16929588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association with 5'-untranslated region and response to interferon in chronic hepatitis C.
    Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
    Hepatogastroenterology; 2007; 54(75):854-7. PubMed ID: 17591078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
    Bressler BL; Guindi M; Tomlinson G; Heathcote J
    Hepatology; 2003 Sep; 38(3):639-44. PubMed ID: 12939590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.